Skip to research content
Back to insiders

Thomas Boesen

Follow this party across linked issuers and source filings.

PartySE · FISweden public disclosures

Companies in disclosed relationships

1

Public filings · 12 months

0

Net disclosed balance · 12 months

€0.00

Latest filing

8 May 2024

Signals are not available for this disclosure jurisdiction.

Recent filings

All disclosed operations, including compensation and transfers. Values can represent transferred assets rather than cash invested.

Recent public filings linked to this insider party
DateCompanyGross reported valueOpen
8 May 2024SynAct Pharma ABBuy

€159,994.40

Buy/sale net: €159,994.40
Open
25 Mar 2024SynAct Pharma ABMixed

SEK 6,887,966.40

Buy/sale net: -SEK 144,900.00
Open
25 Mar 2024SynAct Pharma ABMixed

SEK 1,384,029.60

Buy/sale net: SEK 98,325.00
Open
12 Sept 2023SynAct Pharma ABSell

SEK 2,775,385.40

Buy/sale net: -SEK 2,775,385.40
Open
19 Jun 2023SynAct Pharma ABBuy

SEK 38,679.50

Buy/sale net: SEK 38,679.50
Open
19 Jun 2023SynAct Pharma ABBuy

SEK 39,081.80

Buy/sale net: SEK 39,081.80
Open
6 Jun 2023SynAct Pharma ABDirection unavailable

Not available

Buy/sale net: Not available
Open
17 Jan 2023SynAct Pharma ABBuy

SEK 2,060,604.20

Buy/sale net: SEK 2,060,604.20
Open
17 Jan 2023SynAct Pharma ABDirection unavailable

Not available

Buy/sale net: Not available
Open
Buy

Gross reported value

€159,994.40

Evidence

SynAct Pharma AB

25 Mar 2024
Mixed

Gross reported value

SEK 6,887,966.40

Evidence

SynAct Pharma AB

25 Mar 2024
Mixed

Gross reported value

SEK 1,384,029.60

Evidence

SynAct Pharma AB

12 Sept 2023
Sell

Gross reported value

SEK 2,775,385.40

Evidence

SynAct Pharma AB

19 Jun 2023
Buy

Gross reported value

SEK 38,679.50

Evidence

SynAct Pharma AB

19 Jun 2023
Buy

Gross reported value

SEK 39,081.80

Evidence
Direction unavailable

Gross reported value

Not available

Evidence

SynAct Pharma AB

17 Jan 2023
Buy

Gross reported value

SEK 2,060,604.20

Evidence

SynAct Pharma AB

17 Jan 2023
Direction unavailable

Gross reported value

Not available

Evidence

Network and companies

1 distinct company in the disclosed relationships. Network coverage is a separate preview.